Related Experiment Videos
Female sexual disorders: psychiatric aspects
1Department of Psychiatry, Case Western Reserve School of Medicine, MetroHealth Medical Center, Cleveland, OH 44109, USA. rsegraves@metrohealth.org
Summary
Female sexual dysfunction affects about 30% of women and is linked to psychiatric conditions and medications. Understanding its treatment is crucial for psychiatrists.
Area of Science:
- Psychiatry
- Sexual Medicine
- Pharmacology
Background:
- Female sexual dysfunction (FSD) is a common concern impacting women's quality of life.
- High comorbidity exists between FSD and various psychiatric syndromes.
- Psychiatric medications are frequently associated with the development or exacerbation of FSD.
Purpose of the Study:
- To review current information on female sexual dysfunction relevant to general psychiatric practice.
- To highlight the prevalence, comorbidity, and iatrogenic causes of FSD.
- To inform clinicians about emerging treatment options.
Main Methods:
- Literature search using keywords: sexual dysfunction, prevalence, comorbidity, psychiatric drugs, pharmacotherapy.
- Review of epidemiologic studies and clinical research.
- Synthesis of findings related to FSD in psychiatric populations.
Main Results:
- Approximately 30% of women aged 18-59 report sexual complaints lasting at least three months.
- Significant overlap between FSD and psychiatric disorders was observed.
- Numerous psychiatric drugs were identified as potential contributors to FSD.
- Investigational drug treatments for FSD are emerging.
Conclusions:
- Clinicians must be aware of the prevalence and impact of FSD in psychiatric patients.
- Understanding the relationship between psychiatric medications and FSD is essential for effective patient care.
- Knowledge of FSD treatment is vital for general psychiatric practice.